antigen 85b
Recently Published Documents


TOTAL DOCUMENTS

45
(FIVE YEARS 6)

H-INDEX

15
(FIVE YEARS 1)

Vaccines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1260
Author(s):  
Shihoko Komine-Aizawa ◽  
Satoru Mizuno ◽  
Kazuhiro Matsuo ◽  
Takahiro Namiki ◽  
Satoshi Hayakawa ◽  
...  

The incidence of infections with nontuberculous mycobacteria (NTM) has been increasing worldwide. The emergence of multidrug-resistant NTM is a serious clinical concern, and a vaccine for NTM has not yet been developed. We previously developed a new recombinant Bacillus Calmette–Guérin (rBCG) vaccine encoding the antigen 85B (Ag85B) protein of Mycobacterium kansasii—termed rBCG-Mkan85B—which was used together with a booster immunization with plasmid DNA expressing the same M. kansasii Ag85B gene (DNA-Mkan85B). We reported that rBCG-Mkan85B/DNA-Mkan85B prime–boost immunization elicited various NTM strain-specific CD4+ and CD8+ T cells and induced Mycobacterium tuberculosis-specific immunity. In this study, to investigate the protective effect against M. kansasii infection, we challenged mice vaccinated with a rBCG-Mkan85B or rBCG-Mkan85B/DNA-Mkan85B prime–boost strategy with virulent M. kansasii. Although BCG and rBCG-Mkan85B immunization each suppressed the growth of M. kansasii in the mouse lungs, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination reduced the bacterial burden more significantly. Moreover, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination induced antigen-specific CD4+ and CD8+ T cells. Our data suggest that rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination effectively enhances antigen-specific T cells. Our novel rBCG could be a potential alternative to clinical BCG for preventing various NTM infections.


2021 ◽  
Vol 2 (8) ◽  
pp. 100372
Author(s):  
Arshad Khan ◽  
Ekramy E. Sayedahmed ◽  
Vipul K. Singh ◽  
Abhishek Mishra ◽  
Stephanie Dorta-Estremera ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0213536 ◽  
Author(s):  
Yong Woo Back ◽  
Seunga Choi ◽  
Han-Gyu Choi ◽  
Ki-Won Shin ◽  
Yeo-Jin Son ◽  
...  

2018 ◽  
Vol 86 (8) ◽  
Author(s):  
Naoto Noguchi ◽  
Risa Nakamura ◽  
Shinya Hatano ◽  
Hisakata Yamada ◽  
Xun Sun ◽  
...  

ABSTRACT Interleukin 21 (IL-21) is a pleiotropic common cytokine receptor γ chain cytokine that promotes the effector functions of NK cells and CD8+ T cells and inhibits CD8+ T cell exhaustion during chronic infection. We found that the absolute number of short-lived effector CD8+ T cells (SLECs) (KLRG1high CD127low) decreased significantly in IL-21 receptor-deficient (IL-21R−/−) mice during Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection. Early effector CD8+ T cells (EECs) (KLRG1low CD127low) were normally generated in IL-21R−/− mice after infection. Exhausted CD8+ T cells (PD-1high KLRG1low) were also normally generated in IL-21R−/− mice after infection. Mixed bone marrow (BM) chimera and transfer experiments showed that IL-21R on CD8+ T cells was essential for the proliferation of EECs, allowing them to differentiate into SLECs after BCG infection. On the other hand, the number of SLECs increased significantly after infection with recombinant BCG (rBCG) that secreted an antigen 85B (Ag85B)–IL-21 fusion protein (rBCG–Ag85B–IL-21), but the number of exhausted CD8+ T cells did not change after rBCG–Ag85B–IL-21 infection. These results suggest that IL-21 signaling drives the differentiation of SLECs from EECs but does not inhibit the exhaustion of CD8+ T cells following BCG infection in mice.


2018 ◽  
Vol 15 (1) ◽  
Author(s):  
Wei Zhang ◽  
Qingbo Shu ◽  
Zhen Zhao ◽  
Jia Fan ◽  
Christopher J. Lyon ◽  
...  

2017 ◽  
Vol 112 (2) ◽  
pp. 123-130 ◽  
Author(s):  
Caroline Rizzi ◽  
◽  
Ana Carolina Peiter ◽  
Thaís Larré Oliveira ◽  
Amilton Clair Pinto Seixas Neto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document